HC Wainwright & Co. has recently reiterated its optimistic Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) and raised its price target ...
Atara Biotherapeutics, a renowned biopharmaceutical company, has unveiled its groundbreaking plans for the future. In an exciting development, the company ...
Barclays PLC, a global financial services company, has increased its stake in Atara Biotherapeutics, Inc., a biotechnology firm specializing in ...
Equities research analysts at StockNews.com recently released a research report on Atara Biotherapeutics (NASDAQ:ATRA), providing an analysis of the company's ...
On August 9, 2023, Anthony Butler, an analyst at EF Hutton, expressed his confidence in Atara Biotherapeutics (NASDAQ:ATRA) by reiterating ...
On August 8, 2023, Atara Biotherapeutics (NASDAQ:ATRA) announced its financial results for the second quarter. Unfortunately, the company experienced a ...
On August 8, 2023, Atara Biotherapeutics will unveil its financial results for the second quarter of 2023. Market analysts anticipate ...
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has recently received mixed recommendations from five brokerages, according to a report by Bloomberg.com. Out of ...
Atara Biotherapeutics, Inc. has been the subject of buzz in recent months due to its development of revolutionary therapies for ...
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is a biotechnology company on a mission to develop transformative therapies for patients with serious diseases ...